Companies in #Atopic Dermatitis

Curanex Pharmaceuticals is a developmental-stage pharmaceutical company discovering, developing, and commercializing botanical drugs for inflammatory and other serious diseases. Its lead candidate, Phyto-N, is being advanced across ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout, with a 2026 pipeline expansion into cancer cachexia and advanced cancer supportive care. The company completed GMP manufacturing and toxicology milestones supporting a planned Q4 2026 IND submission for ulcerative colitis. Curanex (formerly Fordman Pharma, renamed November 2023) listed on Nasdaq in August 2025 at $4.00 per share and implemented a 1-for-20 reverse stock split effective August 20, 2026 to maintain listing compliance, reducing shares outstanding to approximately 1.57 million.

Evommune is a US clinical-stage biotechnology company developing therapies for chronic inflammatory diseases. The company's pipeline is led by EVO101, an IRAK4 inhibitor in Phase 2 for chronic spontaneous urticaria and other inflammatory skin conditions, alongside additional earlier-stage programs. Evommune raised a $115M Series C to advance the pipeline.

Kyowa Kirin Co., Ltd. is a Japanese specialty pharmaceutical and biotechnology company under the Kirin Holdings group, focused on developing innovative antibody-based drugs for cancer, kidney disease, immune system diseases, and rare diseases. The company is headquartered in Chiyoda-ku, Tokyo and is a member of the Nikkei 225 stock index. Kyowa Kirin is the Japan-based parent of Kyowa Kirin, Inc. (the US subsidiary), and operates as a research-driven biopharma with multiple approved biologics including poteligeo (mogamulizumab, for cutaneous T-cell lymphoma) and Crysvita (burosumab, for X-linked hypophosphatemia). The company announced a $530M biologics manufacturing facility in Sanford, North Carolina in June 2024 — its first US manufacturing site — which was selected in June 2026 for the FDA PreCheck Pilot Program. Kyowa Kirin's US subsidiary (KKNA) operates the Sanford facility and supports the company's clinical and commercial biologics pipeline including rocatinlimab for atopic dermatitis.

North Immunology is a privately held biotechnology company developing bispecific antibodies that target orthogonal inflammatory pathways in immune and inflammatory diseases. Its lead program, NOR-101, is a half-life-extended IL-13 x IL-18 bispecific antibody in development for atopic dermatitis. The company is going public through a reverse merger with Aethlon Medical.

Turn Therapeutics is a clinical-stage biotechnology company developing targeted, localized, non-systemic therapies for inflammatory and infectious skin diseases. Its lead program, GX-03, is a topical IL-36/IL-31 pathway inhibitor in Phase 2 for moderate-to-severe atopic dermatitis; a July 2026 interim analysis supported expanding Stage 2 enrollment to roughly 120-135 patients, with topline data targeted for Q4 2026 and a Phase 2a study in hidradenitis suppurativa planned. The company's PermaFusion formulation platform is being developed with Medline under a global supply, development and license agreement, and supports a thermostable intranasal vaccine initiative. Turn Therapeutics (formerly Global Health Solutions, renamed in September 2025) completed a direct listing on Nasdaq in October 2025 and named former FDA Commissioner Stephen M. Hahn as Executive Clinical and Regulatory Lead in May 2026.